Baseline and longitudinal biomarkers predict hepatocellular carcinoma in chronic hepatitis C: A cohort study

Figure 1 Flow chart of study design and population. CHC: Chronic hepatitis C; HCC: Hepatocellular carcinoma.

Figure 2 The cumulative incidence of hepatocellular carcinoma stratified according to different fibrosis-4 scores either at baseline or 3-year time point. A: Cumulative incidence of hepatocellular carcinoma (HCC) by baseline fibrosis-4 (FIB-4) score. The 5-, 10-, and 15-year cumulative risk of HCC was 0%, 4.3%, and 4.3% for FIB-4 index < 1.45; 3.2%, 12.2%, and 31.9% in patients with FIB-4 index 1.45-3.25; and 14.2%, 40.2%, and 64.2% in those with FIB-4 index > 3.25, respectively; B: Cumulative incidence of HCC by third-year FIB-4 score. The 5-, 10-, and 15-year cumulative incidence of HCC was 3.0%, 3.0%, and 3.0% for FIB-4 index < 1.45; 7.0%, 23.4%, and 33.9% for FIB-4 index 1.45-3.25; and 19.6%, 48.8%, and 78.1% for FIB-4 > 3.25, respectively. FIB-4: Fibrosis-4.

Figure 3 Cumulative incidence of hepatocellular carcinoma by change in fibrosis-4 group. Increase [change in fibrosis-4 (FIB-4) ≥ +1.0], decrease (ΔFIB-4 ≤ -1.0), stable (-1.0 < ΔFIB-4 < +1.0). The 5-, 10-, and 15-year cumulative incidence of hepatocellular carcinoma was 4.4%, 29.9%, and 72.7% for increase group; 9.2%, 30.7%, and 35.7% for decrease group; and 0%, 12.1%, and 27.1% for stable group, respectively.